New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
Today's noteworthy downgrades include: Advanced Energy (AEIS) downgraded to Hold from Buy at Needham... Allergan (AGN) downgraded to Neutral from Outperform at Credit Suisse... Broadcom (BRCM) downgraded at Stifel... Cash America (CSH) downgraded to Neutral at Janney Capital... Centene (CNC) downgraded to Sell from Neutral at Citigroup... Clovis (CLVS) downgraded to Neutral from Buy at Citigroup... Danone (DANOY) downgraded to Sell from Neutral at Goldman... Heineken (HEINY) downgraded to Sell from Neutral at Goldman... Kosmos (KOS) downgraded to Neutral from Accumulate at Global Hunter... MeadWestvaco (MWV) downgraded to Neutral from Buy at Buckingham... Oil States (OIS) downgraded to Neutral from Positive at Susquehanna... Oxford Lane (OXLC) downgraded to Neutral from Buy at Ladenburg... PHH Corp. (PHH) downgraded to Neutral from Buy at Compass Point... Quiksilver (ZQK) downgraded at Monness Crespi... TPG Specialty Lending (TSLX) downgraded to Market Perform at Wells Fargo... Triangle Petroleum (TPLM) downgraded to Neutral from Buy at Global Hunter... W.R. Grace (GRA) downgraded to Buy from Conviction Buy at Goldman.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
September 29, 2015
13:28 EDTAGNAllergan volatility at 52-week high on share price pull back
Subscribe for More Information
12:33 EDTAGNOn The Fly: Top stock stories at midday
Stocks on Wall Street were slightly higher at midday as the market seeks to break its losing streak, helped by an improvement in consumer confidence that came despite the recent market volatility. ECONOMIC EVENTS: In the U.S., consumer confidence unexpectedly rose in September. Analysts expected the consumer confidence reading to pull back to 96.8 from the prior 101.5 figure, but it actually strengthened to 103.0. The S&P/Case-Shiller 20-city composite home price index was up a seasonally adjusted 0.2% month over month in July, versus the consensus forecast for a rise of 0.1%. Stocks sold off in much of Asia last night, with China's Shanghai composite index sliding 2% while Japan's Nikkei dropped 4%, erasing year-to-date gains in the process. COMPANY NEWS: Shares of Yahoo (YHOO) advanced 3% after its board authorized the company to continue to pursue its spin-off of Aabaco Holdings, a newly formed independent registered investment company that will hold all of Yahoo's remaining holdings in Alibaba Group (BABA). MAJOR MOVERS: Among the notable gainers was Radius Health (RDUS), which rose nearly 10% after Ben Harrington of the Betaville blog stated during an appearance on Tip TV that he has heard that "something will be happening" in terms of M&A involving the company over the "next few weeks." Also higher were several recently beaten down biotech stocks that were seeing some bounceback, including Vertex Pharmaceuticals (VRTX), which gained 5%, and Biogen (BIIB), which advanced 4%. Notably, both of them, along with Amgen (AMGN), were mentioned in a note to investors by Cowen analyst Ken Cacciatore as "hypothetical" targets for Allergan (AGN). Among the noteworthy losers was OvaScience (OVAS), which dropped 38% after saying it now longer expects to meet its 2015 goal of 1,000 Augment cycles. Esperion (ESPR) also fell 38% after the company warned that the FDA could require it to undertake new studies before its ETC-1002 is approved. INDEXES: Near midday, the Dow was up 7.27, or 0.05%, to 16,009.16, the Nasdaq was up 7.38, or 0.16%, to 4,551.35, and the S&P 500 was up 4.56, or 0.24%, to 1,886.33.
10:00 EDTAGNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:29 EDTKOSDeutsche Bank to hold a conference
Subscribe for More Information
08:57 EDTAGNCowen lists Vertex, Biogen and Amgen as hypothetical Allergan targets
Cowen analyst Ken Cacciatore noted that the price agreed for Allergan's (AGN) generic divestiture to Teva (TEVA) is fixed and that the cash value from this deal has not depreciated in any way while the corresponding valuations of potential targets have corrected, increasing the potential value creation available for Allergan as it decides how to deploy its capital. To illustrate the value creation that Allergan's capital deployment could generate, Cacciatore estimates the type of accretion potential that might be seen if the company were to buy Vertex with an acquisition price of $36.5B, if it were to acquire Biogen (BIIB) at a price of $91B or if it were to purchase Amgen (AMGN) with an acquisition price of $140B. Although the market correction has lowered Allergan's stock, the decline could be viewed as a near-term positive, given that a key component of its strategy and business model is to seek to aggressively deploy its capital, Cacciatore argues in a note to investors. The analyst keeps an Outperform rating and $400 price target on Allergan shares.
08:18 EDTAGNAllergan initiated with a Buy at Nomura
Subscribe for More Information
08:03 EDTAGNAllergan price target lowered to $311 from $357 at Leerink
Subscribe for More Information
07:09 EDTAGNAllergan selloff brings 'compelling' buying opportunity, says JPMorgan
Subscribe for More Information
06:37 EDTCNCInvestors feel burn of big M&A deals, WSJ reports
Some investors are getting burned by large acquisitions, the Wall Street Journal reports. The rise in stock prices as a result of the M&A boom over the past few years have had the twin effect of emboldening other buyers and increasing the value of shares that are often used as currency, the report says. Since July 1, buyers' share prices fell about 0.6% on average on the first day of trading following the announcement of an M&A deal over $1B, the report says, citing data provider Dealogic. For example, Energy Transfer Equity's (ETE) stock dropped nearly 13% after news of its $32.6B proposal to take over Williams Companies (WMB), with Centene (CNC), McGraw Hill Financial (MHFI), and Dialog all also falling after M&A news, the report says. Reference Link
September 28, 2015
18:32 EDTTSLXTICC Capital issues revised letter to shareholders
Subscribe for More Information
16:40 EDTAGNAllergan to begin reporting Global Generics business as discontinued ops in Q3
Allergan (AGN) intends to begin reporting its Global Generics business as discontinued operations with its third quarter 2015 results. The transaction with Teva (TEVA) is expected to close in the first quarter of 2016.
16:23 EDTAGNAllergan sees 10% branded revenue growth after divestiture of generics unit
Following the close of the divestiture of the Generics business to Teva (TEVA), New Allergan (AGN) expects to have a powerful financial profile to drive continued long-term growth: 10% branded revenue growth; Non-GAAP gross margins of 77% to 79% with additional long-term expansion anticipated; Non-GAAP SG&A as a percentage of revenue between 21-24%, declining within that range over time; Non-GAAP tax rate of ~15%; Interest expense for New Allergan will be largely dependent on capital deployment decisions following the close of the transaction; Commitment to investment grade ratings. "New Allergan will have strong double-digit revenue growth and will be a development powerhouse stacked with 70 mid-to-late stage R&D projects to address customer and patient needs," said Brent Saunders, CEO and President. "The New Allergan will be lean and nimble with an expanded margin profile driven by leading brands in seven therapeutic categories, a streamlined operating model with one of the most efficient SG&A as a percentage of sales in the industry, a non-GAAP tax rate of approximately 15 percent, and a simplified manufacturing network globally. The continued robust performance of our overall business and strong mid-to-late stage pipeline puts Allergan in a strong position to meet our growth targets for the remainder of the year and over the long-term."
16:21 EDTAGNAllergan sees 2H15 adjusted EPS $6.25-$6.65
Subscribe for More Information
08:21 EDTTSLXTPG Specialty Lending urges TICC investors to vote against management at meeting
Subscribe for More Information
07:52 EDTAGNIIR Holdings to hold a conference
Subscribe for More Information
07:25 EDTOISJohnson Rice to hold a conference
2015 Johnson Rice Energy Conference is being held in New Orleans, Louisiana on September 28-30.
September 25, 2015
08:00 EDTAGNAllergan launches generic version of INVEGA
Allergan announced that it has launched a generic version of Janssen's INVEGA in the U.S. Allergan is the first company to receive FDA approval for and launch a generic version of INVEGA, demonstrating the deep expertise of the Company's global generics R&D, regulatory and supply chain teams.
07:22 EDTCLVSEuropean Society for Medical Oncology to hold a conference
Subscribe for More Information
September 24, 2015
14:17 EDTAGNAppeals court affirms Shire Vyvanse patents valid until 2023
Subscribe for More Information
06:23 EDTHEINYHeineken, Carslberg won't benefit from SABMiller-AB InBev merger, WSJ says
Brewers Heineken (HEINY) and Carlsberg will not likely see any benefit from a proposed merger of SABMiller (SBMRY) and AB InBev (BUD), the Wall Street Journal reports. Analysts have suggested that there are a few takeover opportunities for the two brewers as part of a successful AB InBev takeover of SABMiller, the report says. If options do arise, Heineken would have more to explore than Carlsberg since it is larger and more profitable, the report says. Still, some believe Molson Coors (TAP) is seen as the most likely buyer of any assets from SABMiller, including its stake in their joint venture MillerCoors, the report says. Reference Link
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use